CIC
CCCC icon

Cornercap Investment Counsel’s C4 Therapeutics CCCC Stock Holding History

Cornercap Investment Counsel’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-11,791
Closed -$67.2K – 479
2024
Q3 		$67.2K Sell
11,791
-15,345
-57% -$92.3K 0.02% 499
2024
Q2 		$125K Buy
+27,136
New +$162K 0.02% 567
2024
Q1 		– Sell
-46,286
Closed -$262K – 617
2023
Q4 		$262K Sell
46,286
-1,170
-2% -$2.67K 0.04% 498
2023
Q3 		$88.3K Sell
47,456
-591
-1% -$1.8K 0.02% 537
2023
Q2 		$132K Hold
48,047
– – 0.02% 540
2023
Q1 		$151K Buy
48,047
+21,756
+83% +$128K 0.03% 525
2022
Q4 		$155K Buy
26,291
+4,690
+22% +$38.9K 0.03% 524
2022
Q3 		$189K Buy
21,601
+1,203
+6% +$12.5K 0.04% 502
2022
Q2 		$154K Buy
+20,398
New +$179K 0.03% 502

Other funds holding CCCC

SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Cornercap Investment Counsel's CCCC Position: Q4 2024 in Review

Cornercap Investment Counsel sold out of C4 Therapeutics (CCCC) in Q4 2024, closing a stake of 11,791 shares — an estimated $67.2K sold.

Cornercap Investment Counsel first reported a position in CCCC in Q2 2022 and held it in 9 quarters. The position peaked at $262K in Q4 2023. 113 funds tracked by Wall St. Rank hold CCCC as of Q4 2024.

  • Cornercap Investment Counsel reported no remaining C4 Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Cornercap Investment Counsel sold 11,791 C4 Therapeutics shares in Q4 2024, an estimated $67.2K.
  • Cornercap Investment Counsel first reported a position in C4 Therapeutics in Q2 2022 and held it in 9 quarters.
  • Cornercap Investment Counsel's C4 Therapeutics position peaked at $262K in Q4 2023.
  • 113 funds tracked by Wall St. Rank held C4 Therapeutics as of Q4 2024.

Based on Cornercap Investment Counsel's 13F filing for Q4 2024, filed 12 Feb 2025.